))
Endometrial Cancer New FIGO Stage IA3 vs IIIA1 with Koji Matsuo
Manage episode 420540251 series 3480180
Content provided by BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Koji Matsuo to discuss new FIGO staging of endometrial cancer. Dr. Matsuo is a clinician-scientist in the area of gynecologic oncology in the United States. His research interest is population-based, heath service outcome research for gynecologic malignancies.
Highlights:
(1) Survival effect of adjuvant therapy differed between stage IA3 and IIIA1.
(2) In new stage IA3 disease, omission of adjuvant therapy had comparable overall survival compared to combination chemotherapy and external beam radiotherapy or chemotherapy alone.
(3) In stage IIIA1, omission of adjuvant therapy was associated with decreased overall survival compared to chemotherapy-based approach.
(4) 5-year overall survival of adjuvant therapy omission group in new stage IA3 was nearly 90%.
(5) These hypothesis-generating observation suggested that treatment de-escalation of well-staged stage IA3 may not adversely affect survival.
365 episodes
Share
